JP2016526531A5 - - Google Patents

Download PDF

Info

Publication number
JP2016526531A5
JP2016526531A5 JP2016518498A JP2016518498A JP2016526531A5 JP 2016526531 A5 JP2016526531 A5 JP 2016526531A5 JP 2016518498 A JP2016518498 A JP 2016518498A JP 2016518498 A JP2016518498 A JP 2016518498A JP 2016526531 A5 JP2016526531 A5 JP 2016526531A5
Authority
JP
Japan
Prior art keywords
dose
administered
viral particles
particles per
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016518498A
Other languages
English (en)
Japanese (ja)
Other versions
JP6797680B2 (ja
JP2016526531A (ja
Filing date
Publication date
Priority claimed from GB201310698A external-priority patent/GB201310698D0/en
Priority claimed from GB201405140A external-priority patent/GB201405140D0/en
Priority claimed from GB201406509A external-priority patent/GB201406509D0/en
Application filed filed Critical
Priority claimed from PCT/EP2014/062284 external-priority patent/WO2014198852A2/en
Publication of JP2016526531A publication Critical patent/JP2016526531A/ja
Publication of JP2016526531A5 publication Critical patent/JP2016526531A5/ja
Priority to JP2020151615A priority Critical patent/JP7860685B2/ja
Application granted granted Critical
Publication of JP6797680B2 publication Critical patent/JP6797680B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016518498A 2013-06-14 2014-06-12 Ｂ型アデノウイルスのための投与計画および製剤 Active JP6797680B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2020151615A JP7860685B2 (ja) 2013-06-14 2020-09-09 Ｂ型アデノウイルスのための投与計画および製剤

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB201310698A GB201310698D0 (en) 2013-06-14 2013-06-14 Method
GB1310698.4 2013-06-14
GB201405140A GB201405140D0 (en) 2014-03-22 2014-03-22 Method
GB1405140.3 2014-03-22
GB1406509.8 2014-04-10
GB201406509A GB201406509D0 (en) 2014-04-10 2014-04-10 Method
PCT/EP2014/062284 WO2014198852A2 (en) 2013-06-14 2014-06-12 A dosing regime and formulations for type b adenoviruses

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020151615A Division JP7860685B2 (ja) 2013-06-14 2020-09-09 Ｂ型アデノウイルスのための投与計画および製剤

Publications (3)

Publication Number Publication Date
JP2016526531A JP2016526531A (ja) 2016-09-05
JP2016526531A5 true JP2016526531A5 (enExample) 2016-10-20
JP6797680B2 JP6797680B2 (ja) 2020-12-16

Family

ID=51162703

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016518498A Active JP6797680B2 (ja) 2013-06-14 2014-06-12 Ｂ型アデノウイルスのための投与計画および製剤
JP2020151615A Active JP7860685B2 (ja) 2013-06-14 2020-09-09 Ｂ型アデノウイルスのための投与計画および製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020151615A Active JP7860685B2 (ja) 2013-06-14 2020-09-09 Ｂ型アデノウイルスのための投与計画および製剤

Country Status (12)

Country Link
US (3) US11173186B2 (enExample)
EP (2) EP3007711B1 (enExample)
JP (2) JP6797680B2 (enExample)
KR (3) KR20160026970A (enExample)
CN (2) CN105431157A (enExample)
AU (2) AU2014280123B2 (enExample)
BR (1) BR112015030881A2 (enExample)
CA (2) CA2914790C (enExample)
IL (1) IL243071B (enExample)
RU (1) RU2671558C2 (enExample)
SG (1) SG11201510064WA (enExample)
WO (1) WO2014198852A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201510197D0 (en) 2014-06-12 2015-07-29 Psioxus Therapeutics Ltd Method of treating ovarian cancer
WO2018182014A1 (ja) * 2017-03-31 2018-10-04 久修 緒方 腫瘍溶解性ウイルスの増殖方法及び抗腫瘍剤
GB201801614D0 (en) * 2018-01-31 2018-03-14 Psioxus Therapeutics Ltd Formulation
CN118001307A (zh) * 2018-03-30 2024-05-10 藤堂具纪 肿胀发生抑制型溶瘤病毒
WO2021067310A1 (en) * 2019-09-30 2021-04-08 Candel Therapeutics, Inc. Combination gmci and atri cancer treatment
CN114469938A (zh) * 2020-10-27 2022-05-13 中国医学科学院药物研究所 化合物bix02189在制备抗流感病毒药物中的应用
CN114601838B (zh) * 2022-04-29 2023-10-27 广东龙帆生物科技有限公司 一种azd8055在制备用于抗腺病毒感染的药物中的用途
WO2024042231A1 (en) * 2022-08-26 2024-02-29 Universite De Namur Adenovirus-based adjuvants for cancer treatment
AU2024277678A1 (en) 2023-05-25 2025-11-27 Dispatch Biotherapeutics, Inc. Synthetic cancer antigens as targets for treating cancers
WO2025171388A1 (en) 2024-02-09 2025-08-14 Dispatch Biotherapeutics, Inc. Engineered cancer antigens with modified domains and related methods and uses
WO2025171383A2 (en) 2024-02-09 2025-08-14 Dispatch Biotherapeutics, Inc. Engineered cancer antigens and related methods and uses
WO2026117756A2 (en) 2024-11-27 2026-06-04 Dispatch Biotherapeutics, Inc. Systems and methods for expression of synthetic cancer antigens and cytokine receptors
WO2026117753A1 (en) 2024-11-27 2026-06-04 Dispatch Biotherapeutics, Inc. Viral vectors for expression of synthetic cancer antigens and chemokine and related methods and uses

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0170269A3 (en) 1984-08-02 1987-09-23 Kao Corporation Medicated cosmetic compositions
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
DE19648650C2 (de) 1996-01-29 1998-07-02 Schering Ag Puffersysteme und deren Verwendung zur Stabilisierung pharmazeutischer Zubereitung
GB9623051D0 (en) 1996-11-06 1997-01-08 Schacht Etienne H Delivery of DNA to target cells in biological systems
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
EP1905304A3 (en) * 1997-10-09 2008-08-13 Wellstat Biologics Corporation Treatment of neoplasms with viruses
US20030044384A1 (en) * 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
US6689600B1 (en) 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
AU774076C (en) 1998-12-09 2005-04-14 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The A recombinant vector expressing multiple costimulatory molecules and uses thereof
CA2364934C (fr) 1999-02-22 2011-10-18 Transgene S.A. Procede d'obtention d'une preparation virale purifiee
WO2000061726A1 (fr) 1999-04-09 2000-10-19 Aventis Pharma S.A. Composition destinee a la conservation d'adenovirus recombinants infectieux
GB9913359D0 (en) 1999-06-09 1999-08-11 Cancer Res Campaign Tech Polymer modified biological elements
US6596535B1 (en) 1999-08-09 2003-07-22 Targeted Genetics Corporation Metabolically activated recombinant viral vectors and methods for the preparation and use
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
EP1327688A1 (en) 2002-01-14 2003-07-16 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Adenoviruses with enhanced lytic potency
US20040167088A1 (en) * 2003-02-25 2004-08-26 Genvec, Inc. Method of using adenoviral vectors with increased persistence in vivo
EP1646717A4 (en) * 2003-07-18 2006-12-20 Onyx Pharma Inc ADENOVIRAL VECTORS OF SUB-GROUP B FOR THE TREATMENT OF DISEASES
US8076459B2 (en) 2003-10-16 2011-12-13 Micromet Ag Multispecfic deimmunized CD3-binders
CN1922308A (zh) 2004-02-23 2007-02-28 克鲁塞尔荷兰公司 病毒纯化方法
ES2358204T3 (es) * 2004-05-26 2011-05-06 Bayer Schering Pharma Aktiengesellschaft Adenovirus quiméricos para uso en el tratamiento del cáncer.
GB0416487D0 (en) 2004-07-23 2004-08-25 Isis Innovation Modified virus
EP1819823A2 (en) 2004-12-01 2007-08-22 Bayer Schering Pharma Aktiengesellschaft Generation of replication competent viruses for therapeutic use
US20060205080A1 (en) 2005-03-01 2006-09-14 David Frey Formulations for therapeutic viruses having enhanced storage stability
US8765146B2 (en) 2005-08-31 2014-07-01 Genvec, Inc. Adenoviral vector-based malaria vaccines
CN1961961B (zh) 2005-11-11 2010-05-26 深圳市源兴生物医药科技有限公司 一种药物制剂及其制备方法
RU2382884C2 (ru) 2006-07-10 2010-02-27 Александр Владимирович Дидин Сферическая объемная роторная машина и способ работы сферической объемной роторной машины
JP5448840B2 (ja) * 2006-12-22 2014-03-19 プシオクサス・セラピューティクス・リミテッド 腫瘍退縮アデノウイルスの作出およびその使用
WO2009097443A2 (en) 2008-01-29 2009-08-06 Remedy Pharmaceuticals, Inc. Liquid formulations of compounds active at sulfonylurea receptors
US20110086005A1 (en) * 2008-05-27 2011-04-14 Oncolytics Biotech Inc. Modulating interstitial pressure and oncolytic viral delivery and distribution
BRPI0920707A2 (pt) 2008-10-02 2015-12-29 Respivert Ltd compostos
CN101381742A (zh) 2008-10-23 2009-03-11 浙江理工大学 晚期启动子靶向性调控溶瘤腺病毒pCN305载体及其构建方法与应用
CN102245215A (zh) 2008-12-11 2011-11-16 普西奥库斯治疗有限公司 用包含带电荷的季氨基的聚合物的核酸载体的修饰
GB0918249D0 (en) 2009-10-19 2009-12-02 Respivert Ltd Compounds
LT2748201T (lt) 2011-08-23 2018-02-26 Roche Glycart Ag Dvigubai specifinė t ląsteles aktyvinantį antigeną surišanti molekulė
JP2015507604A (ja) 2011-11-14 2015-03-12 リジェネレイティブ サイエンシーズ， エルエルシー 懸濁粒子送達システムおよび方法
PL2844282T3 (pl) 2012-05-04 2019-11-29 Pfizer Antygeny związane z gruczołem krokowym i schematy immunoterapii oparte na szczepionce
US9314519B2 (en) 2012-08-21 2016-04-19 Intervet Inc. Liquid stable virus vaccines
WO2015040234A1 (en) 2013-09-23 2015-03-26 Crucell Holland B.V. Adenovirus formulations
KR102272932B1 (ko) 2013-10-25 2021-07-05 싸이오서스 테라퓨틱스 엘티디. 이종 유전자로 무장된 종양살상 아데노바이러스
EP4011910A1 (en) 2014-04-03 2022-06-15 IGM Biosciences, Inc. Modified j-chain
KR20170044194A (ko) 2014-08-27 2017-04-24 싸이오서스 테라퓨틱스 엘티디. 아데노바이러스의 제조를 위한 공정
DK3288573T3 (da) 2015-04-30 2020-03-16 Psioxus Therapeutics Ltd Onkolytisk adenovirus, der koder for et b7-protein

Similar Documents

Publication Publication Date Title
RU2015152860A (ru) Режим введения и составы для аденовирусов типа в
Yasinjan et al. Immunotherapy: a promising approach for glioma treatment
Basak et al. Tumor-associated macrophages: an effective player of the tumor microenvironment
Zhu et al. Improving cancer immunotherapy by rationally combining oncolytic virus with modulators targeting key signaling pathways
Huang et al. Time-programmed delivery of sorafenib and anti-CD47 antibody via a double-layer-gel matrix for postsurgical treatment of breast cancer
Seicean et al. New targeted therapies in pancreatic cancer
JP2012067116A5 (enExample)
JP2019065028A5 (enExample)
JP2016530280A5 (enExample)
JP2017031213A5 (enExample)
JP2013189456A5 (enExample)
JP2020509024A5 (enExample)
JP2015187125A5 (enExample)
RU2015144666A (ru) Терапия для лечения рака, включающая антитела против клаудина 18.2
Niedbała et al. Glioblastoma: pitfalls and opportunities of immunotherapeutic combinations
Karapetyan et al. Radiation dose, schedule, and novel systemic targets for radio-immunotherapy combinations
Frieboes et al. Chloroquine-mediated cell death in metastatic pancreatic adenocarcinoma through inhibition of autophagy
JP2016515586A5 (enExample)
JP2016501528A5 (enExample)
Holtermann et al. Prospects of Synergy: Local Interventions and CAR T Cell Therapy in Solid Tumors: A. Holtermann et al.
JP2017503846A5 (enExample)
Jiang et al. Low‐dose Apatinib promotes vascular normalization and hypoxia reduction and sensitizes radiotherapy in lung cancer
Warricker et al. The role of NK cells in oncolytic viral therapy: a focus on hepatocellular carcinoma
He et al. Role of tumor-associated macrophages in breast cancer immunotherapy
Sun et al. Combining immunotherapy with radiotherapy for glioblastoma: recent advances and challenges